Safe­ty threat forces Enan­ta to scrap HBV tri­als — send­ing dis­cov­ery team back to draw­ing board

A Mass­a­chu­setts biotech will dis­con­tin­ue the de­vel­op­ment of its oral drug in­tend­ed to treat pa­tients suf­fer­ing from chron­ic he­pati­tis B in­fec­tions, the com­pa­ny said Thurs­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER